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Abstract
The BRG1 catalytic subunit of SWI/SNF-related complexes is required for mammalian development as exemplified by the
early embryonic lethality of Brg1 null homozygous mice. BRG1 is also a tumor suppressor and, in mice, 10% of heterozygous
(Brg1
null/+) females develop mammary tumors. We now demonstrate that BRG1 mRNA and protein are expressed in both the
luminal and basal cells of the mammary gland, raising the question of which lineage requires BRG1 to promote mammary
homeostasis and prevent oncogenic transformation. To investigate this question, we utilized Wap-Cre to mutate both Brg1
floxed alleles in the luminal cells of the mammary epithelium of pregnant mice where WAP is exclusively expressed within
the mammary gland. Interestingly, we found that Brg1
Wap-Cre conditional homozygotes lactated normally and did not
develop mammary tumors even when they were maintained on a Brm-deficient background. However, Brg1
Wap-Cre mutants
did develop ovarian cysts and uterine tumors. Analysis of these latter tissues showed that both, like the mammary gland,
contain cells that normally express Brg1 and Wap. Thus, tumor formation in Brg1 mutant mice appears to be confined to
particular cell types that require BRG1 and also express Wap. Our results now show that such cells exist both in the ovary
and the uterus but not in either the luminal or the basal compartments of the mammary gland. Taken together, these
findings indicate that SWI/SNF-related complexes are dispensable in the luminal cells of the mammary gland and therefore
argue against the notion that SWI/SNF-related complexes are essential for cell survival. These findings also suggest that the
tumor-suppressor activity of BRG1 is restricted to the basal cells of the mammary gland and demonstrate that this function
extends to other female reproductive organs, consistent with recent observations of recurrent ARID1A/BAF250a mutations in
human ovarian and endometrial tumors.
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Introduction
Mammalian SWI/SNF chromatin-remodeling complexes reg-
ulate many cellular processes and function as tumor suppressors.
Notably, the BRG1, BRM, SNF5, ARID1A/BAF250a, PBRM1/
BAF180, and Srg3/Baf155 subunits are consistently mutated or
silenced in certain primary human tumors and also protect
against tumorigenesis in mouse models [1–4]. Further evidence of
the tumor-suppressor role of these genes has come from
experiments showing that restoration of wild-type expression of
the mutated or silenced subunit in tumor-derived cell lines can
decrease proliferation and promote differentiation [5]. Mecha-
nistically, several SWI/SNF subunits have been shown to
physically interact with known tumor-suppressor genes and
proto-oncogenes or their encoded proteins [1–3]. These studies
include the demonstrated ability of the BRG1 catalytic subunit
(also known as SMARCA4) and SNF5 (also known as BRG1-
associated factor 47 or BAF47) to bind to the promoters of
the p15
INK4b (known as p19 in the mouse), p16
INK4a, and
p21
CIP1/WAF1 cyclin-dependent kinase (CDK) inhibitors and
activate expression of these target genes [6–10]. This, in turn,
leads to an inhibition of CDK2 or CDK4 and an accumulation of
hypophosphorylated RB. BRG1 and an alternative catalytic
subunit, BRM (also known as SMARCA2), can also bind to
hypophosphorylated RB and are required to repress the activity
of E2F1, inhibit the transcription of cyclins A and E, and mediate
G1 cell-cycle arrest [11–15].
We previously showed that the homozygous Brg1 null genotype
is embryonic lethal in mice and 10% of Brg1 null heterozygous
mice spontaneously develop mammary tumors at approximately
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31346one year of age without prior exposure to ionizing radiation (IR)
or other known oncogenic agents [16,17]. These tumors do not
show loss of heterozygosity (LOH) at the Brg1 locus but do exhibit
genomic instability suggesting that the acquisition of secondary
mutations in addition to Brg1 haploinsufficiency helps drive the
development of the mammary tumors obtained. Interestingly,
these Brg1
null/+ mammary tumors are more heterogeneous in
terms of their histopathology, cytokeratin expression, and
transcriptome profiles than the mammary tumors that arise in
other mouse models of breast cancer [17]. To further investigate
t h er o l eo fBrg1 as a tumor suppressor, we now report the results
of experiments that demonstrate a relationship between the
normal transcriptional activity of the Brg1, Brm and Whey acidic
protein (Wap) genes, and the effect on viability and transformation
of Wap-activated deletion of Brg1 in the presence or absence of
Brm.
Results
Brg1 and Brm are co-expressed in all mammary epithelial
cells, whereas Wap expression is confined to the luminal
cells of the mammary gland in pregnant mice
In a first series of experiments, we sought to characterize the
expression of Brg1, Brm, and Wap in different subsets of mammary
cells in normal adult virgin and pregnant female mice.
Accordingly, we dissociated their mammary gland fat pads into
single-cell suspensions, removed hematopoietic, endothelial, and
stromal cells, and subdivided the mammary epithelial cells into 3
fractions according to their levels of expression of CD24 and
CD49f as described [18]. Representative fluorescent activated cell
sorter (FACS) plots of the cells isolated for this analysis are shown
in Figure 1A for cells from normal virgin mice and in Figure S1 for
cells from pregnant mice. We then determined the levels of Brg1,
Figure 1. Expression of Brg1, Brm, and Wap in CD45
2Ter119
2CD31
2 mammary gland subpopulations. A. Representative FACS plot of
the subpopulations remaining after removing the hematopoietic and endothelial (CD45
+Ter119
+CD31
+) cells from a suspension prepared from
dissociated mammary tissue from a normal adult virgin mouse. The CD24
+CD49f
low/2 subset is enriched in luminal (Lum) cells; the CD24
+CD49f
+
subset is enriched in mature myoepithelial (Myo) cells; and the CD24
+CD49
high subset is enriched in mammary stem cells (referred to as mammary
repopulating units or MRU). B, C. RT-qPCR analysis of Brg1 (B) and Brm (C) mRNA levels normalized to Gapdh levels in wild-type, flow-sorted mammary
cell populations from adult virgin female mice. The Lum, Myo, and MRU subsets are as defined in panel A. Each histogram represents the mean 6 SE
from 3 independent experiments. D. RT-qPCR analysis of Wap mRNA levels normalized to Gapdh mRNA levels measured in the same 3 subsets. Lum,
Myo, and MRU cells were isolated from pregnant females (E17.5 and E13.5) and virgin/nulliparous females (for representative FACS plots, see Figure 1).
Asterisks indicate that the Wap signal was below the limit of detection. Each histogram represents the mean 6 SE from 2 (E17.5) or 3 (E13.5, virgin/
nulliparous) independent experiments.
doi:10.1371/journal.pone.0031346.g001
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qPCR. As shown in Figure 1B, we found Brg1 transcripts are
present at readily detectable levels in all 3 fractions of normal
adult virgin mice with the highest levels of expression in the
CD24
+CD49f
low/2 (luminal cell-enriched) subset of cells and 2- to
3-fold lower levels in the CD24
+CD49f
+ and CD24
+CD49f
high
subsets, respectively. The latter 2 subpopulations are selectively
enriched in mature myoepithelial cells and mammary stem cells
(defined by their mammary repopulating activity in the cleared fat
pad transplantation assay), respectively [18]. We found Brm is also
expressed in all 3 of these same subpopulations (Figure 1C). This
overlap in Brg1 and Brm expression is similar to other adult tissues
[19].
We then analyzed the same subsets of mammary cells for
expression of the Wap gene. We found Wap is highly expressed
in the CD24
+CD49f
low/2 (luminal) mammary cells during late
Table 1. Phenotype of Brg1
Wap-Cre mutant mice.
Phenotype
Gender Category Genotype
1 #Litters* Mammary Ovary/Uterus
Male control +/floxed, Tg N/A none N/A
Male control
2 null/floxed, Tg N/A none N/A
Male control
2 null/floxed, Tg N/A none N/A
Male control
2 floxed/floxed, Tg N/A none N/A
Female control floxed/floxed 4 none none
3
Female control +/null, Tg 4 none none
Female control +/+, Tg 4 none none
Female control +/+, Tg 4 none none
Female control +/floxed, Tg 2 none none
Female control +/null 4 none none
Female control null/floxed 3 none none
Female control null/floxed 3 none none
Female control null/floxed 3 none none
Female control +/floxed, Tg 3 none none
Female control null/floxed 2 none none
Female control floxed/floxed 2 none none
Female mutant null/floxed, Tg 4 none uterine tumor
Female mutant null/floxed, Tg 4 none ovarian cyst
Female mutant null/floxed, Tg 4 none ovarian cyst, uterine tumor
Female mutant null/floxed, Tg 2 none uterine tumor
Female mutant null/floxed, Tg 3 none ovarian cyst
Female mutant null/floxed, Tg 3 none none
Female mutant floxed/floxed, Tg 4 none none
Female mutant floxed/floxed, Tg 3 none ovarian cyst
Female mutant floxed/floxed, Tg 3 none ovarian cyst, uterine tumor
Female mutant floxed/floxed, Tg 3 none ovarian cyst
Female mutant floxed/floxed, Tg 3 none ovarian cyst
Female mutant null/floxed, Tg 3 none ovarian cyst
Female mutant floxed/floxed, Tg 2 none ovarian cyst
Female mutant floxed/floxed, Tg 3 none ovarian cyst
Female mutant floxed/floxed, Tg 3 none ovarian cyst
Female mutant null/floxed, Tg 3 none ovarian cyst
Female mutant floxed/floxed, Tg 3 none ovarian cyst
Female mutant null/floxed, Tg 2 none ovarian cyst
Female mutant null/floxed, Tg 2 none ovarian cyst
Female mutant null/floxed, Tg 2 none ovarian cyst
Female mutant floxed/floxed, Tg 2 none none
*First pregnancy was at 2–3 months of age, and all mice were analyzed at 15–19 months of age.
1Tg was hemizygous in each case (Wap-Cre
+/0).
2Mutant genotypically but considered a control because Cre transgene expression is induced by pregnancy, which does not occur in males.
3Did not score for ovarian or uterine phenotype.
doi:10.1371/journal.pone.0031346.t001
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virgin/nulliparous females (Figure 1D). This is consistent with the
known period of hormonally-induced Wap expression [20]. Wap
transcripts were also not detectable in either of the other 2 subsets
of basal mammary epithelial cells (Figure 1D). These findings
predicted that a Wap-Cre transgene would delete Brg1 only in the
luminal cells of the mammary gland of mice and not until the mice
had reached a late stage of pregnancy.
Luminal mammary cells lacking Brg1 remain viable and
fully functional and do not generate tumors
To evaluate the function of BRG1 in the luminal lineage, we
generated 21 female mice carrying a floxed Brg1 gene and a Wap-
Cre transgene [21,22] (either as Brg1
fl/fl:Wap-Cre
+/0 mice or as
Brg1
null/fl:Wap-Cre
+/0 mice, hereafter referred to as Brg1
Wap-Cre
mutants), and then monitored them for 15–19 months without
exposure to IR or any other known oncogenic agents. To delete
Brg1 in the luminal cells, we mated all 21 females several times,
starting at 2–3 months of age. Twelve littermates were monitored
in parallel as controls. All of the females produced at least 2 litters
each, and none showed any evidence of subsequent abnormalities.
In particular, none of the mice developed any signs of mammary
tumor formation (Table 1). Whole-mount preparations of their
mammary glands removed after 15–19 months also did not reveal
any evidence of microscopic tumors or altered morphology of their
mammary glands (Figure 2A).
PCR assays of cells harvested from the mice at the end of the
Brg1
Dfl allele monitoring period confirmed that the Brg1
fl allele had
been converted to a recombined in mammary glands from
multiparous but not nulliparous females (Figure 2B). Detection of
the fl allele in the PCR assays was not unexpected because
mammary epithelial cells are embedded in a fat pad that also
contains lymph nodes and blood vessels, and Wap-Cre is not
expressed in adipocytes, lymphocytes, or other stromal cells such
as fibroblasts. The Brg1
Dfl PCR product also could not be detected
in tail tissue from either multiparous or nulliparous females
(Figure 2B) consistent with the target specificity of action of the
Wap-Cre transgene [22–24].
To further characterize the mammary cells in which Brg1 is
deleted in Brg1
Wap-Cre mutants, we introduced the Rosa26 reporter
(R26R) gene into the Brg1
Wap-Cre mice [25]. X-Gal staining of tissue
removed from multiparous females that were not at that time
either pregnant, lactating, or involuting confirmed that the Wap-
activated Cre activity had been restricted to the luminal cells of the
Figure 2. Lineage-specific deletion of Brg1 in the mammary gland. A. Whole-mount preparation of control (top) and mutant (bottom)
mammary glands from multiparous females. Asterisks, lymph nodes. B. Ethidium bromide-stained gels showing Brg1 Dfl (top) and fl (bottom) PCR
products. MW, molecular-weight standard (500-, 400-, 300-, 200-, and 75-bp fragments are visible); MG, mammary gland; NP, nulliparous; MP,
multiparous. C. Mammary gland section from multiparous mouse carrying the Wap-Cre transgene on a R26R background. Cre activity, visualized as
blue X-Gal staining, is restricted to luminal cells (arrowhead). Basal/myoepithelial cells (arrow) are negative and appear pink because of nuclear fast
red counterstain. D, E. IHC staining of BRG1 showing strong staining in nuclei throughout the mammary gland in controls (D) but absent in luminal
cells of mutant mice (E). Arrows, luminal cells; asterisks, adipocyte nuclei. 4006magnification.
doi:10.1371/journal.pone.0031346.g002
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histochemical (IHC) studies of sections of mammary tissue from
multiparous Brg1
Wap-Cre mutants and control nulliparous mice.
These experiments showed that the usually strong and widespread
nuclear staining for BRG1 protein (Figure 2D and Figure S2A)
was diminished or absent in the luminal cells of the conditional
mutants while persisting in stromal cells of the same animals where
Wap-Cre is not expressed and Brg1 was not mutated (Figure 2E).
Taken together, these results demonstrate that Brg1 is mutated in
the expected luminal lineage cell-specific manner and argues
strongly against a defect in Cre-mediated recombination as an
explanation for the lack of mammary tumors in Brg1
Wap-Cre mutant
mice.
Mammary luminal cells lacking Brg1 do not undergo
aberrant apoptosis
It was reported that a heterozygous deletion of Brg1 in certain
lung cells, makes them prone to urethane-induced tumorigenesis,
whereas a homozygous deletion of Brg1 in the same cells does not
because the homozygous deletion induces apoptosis [26]. To
investigate whether aberrant apoptosis (unrelated to involution)
might account for the lack of mammary tumors in Brg1
Wap-Cre
mutant mice, we performed TUNEL assays on mammary glands
harvested from multiparous females that were not pregnant,
lactating, or involuting at the time. In controls, we observed
minimal apoptosis as only 0.25% of the mammary epithelial cells
were TUNEL-positive (Figure 3A), which is consistent with
previous reports of wild-type mammary glands [27]. And in
contrast to the lung tumor study, we did not detect a significant
difference in the frequency of apoptosis in mutants, where only
0.20% of the cells were TUNEL positive (Figure 3B). In these
experiments, a leukemia cell line induced to undergo apoptosis
served as a positive control for the TUNEL staining (Figure 3C).
We also performed qPCR analyses to determine whether Brg1-
deleted cells are significantly underrepresented when the abun-
dance of the Dfl PCR product in mammary gland tissue from
conditional homozygous (Brg1
fl/fl:Wap-Cre
+/0) and conditional
heterozygous (Brg1
fl/+:Wap-Cre
+/0) multiparous females was com-
pared. Unlike the lung cancer study, which reported a 1:8 ratio of
Dfl PCR product in homozygous versus heterozygous mice [26],
we obtained a ,2:1 ratio of Dfl PCR product in a comparison of
our homozygous and heterozygous mice, which was what was
expected if the Dfl/Dfl cells were not being strongly selected
against by activation of either apoptosis or necrosis mechanisms
(Figure 3D).
Finally, we noted that every Brg1
Wap-Cre mutant female that
became pregnant not only delivered a healthy litter but was also
able to lactate and raise normal-sized pups. This finding indicates
that the alveolar cell proliferation and differentiation that underlies
mammary gland development during pregnancy and lactation had
not been impaired in spite of the lack of Brg1 expression. A
significant increase in apoptosis would have resulted in insufficient
Figure 3. Mutant luminal cells do not undergo aberrant apoptosis. A, B. TUNEL assay of control (A) and mutant (B) adult mammary gland
sections counterstained with methyl green. C. Lymphocytes induced to undergo apoptosis have brown nuclei (arrow) and serve as a positive control.
D. qPCR analysis of Brg1 Dfl genomic DNA levels normalized to Gapdh genomic DNA levels in mammary glands. Each histogram represents the mean
6 SE from 3 independent experiments.
doi:10.1371/journal.pone.0031346.g003
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as observed for mammary-specific mutations of other genes [28–
33]. Thus, overall we could not find any evidence of decreased
viability of Brg1-deficient luminal cells.
Brm is not required to compensate for the loss of Brg1 in
luminal mammary cells
BRG1 and BRM are 75% identical, broadly expressed, and
serve as alternative catalytic subunits of SWI/SNF-related
complexes with similar or identical activities [34–35]. To
determine whether the lack of a phenotype in Brg1-deleted
luminal mammary cells might be explained by functional
compensation from the co-expressed Brm, we transferred the
Brg1
Wap-Cre mutation onto a Brm-deficient background. We then
monitored 8 double-mutant females and 6 control (non-transgenic)
females for 15–19 months without exposure of either to IR or any
other known oncogenic agents (Table 2). To inactivate Brg1 in
each of the 14 females, a first pregnancy was initiated at 2–3
months of age, and then again 1–2 times subsequently. From each
of these mice, 2–3 litters of normal sized pups were obtained,
indicating that the luminal cells of the mammary gland can remain
viable and completely functional even when neither Brg1 nor Brm
is present. Nor did any of these mice develop mammary tumors
(Table 2). These results demonstrate that the ‘‘normal’’ phenotype
of Brg1 null luminal cells is not due to a compensatory activity
being provided by Brm nor are either of these catalytic subunits
required to prevent these cells from generating tumors.
Mammary tumor induction caused by inhibition of the
RB pathway is not altered by Wap-Cre-mediated deletion
of Brg1 in luminal cells
BRG1 interacts with RB and is required for RB-mediated
growth arrest in tumor-derived cell lines in vitro [11–15]. However,
it is not clear whether this mechanism applies to cancer prevention
in vivo. In a previous study, we noted that the induction of Rb
+/2
mammary tumors was not altered on a Brg1
null/+ background [17].
To determine whether this would also extend to Brg1 null luminal
cells, we crossed Wap-T121 transgenic mice with our Brg1
Wap-Cre
mutants and then monitored them for tumor formation. T121
contains the first 121 amino acids of the SV40 large T antigen,
which binds to RB as well as the other 2 pocket proteins (p107 and
p130) and perturbs their function [32]. Wap-T121 mice express
this transgene in their mammary luminal cells and develop
aggressive mammary tumors with 100% penetrance by ,16
months of age [32]. We confirmed this finding but observed no
further change in the penetrance or latency (Figure S3) or the
histopathologic characteristics (data not shown) of the tumor
phenotype in 10 Wap-T121, Brg1
Wap-Cre double mutant mice as
compared to mice expressing only Wap-T121.
Wap-Cre-mediated deletion of Brg1 induces ovarian cysts
and uterine tumor formation
Although Brg1
Wap-Cre multiparous females are not predisposed to
develop breast cancer, we discovered that they do develop grossly
visible ovarian cysts and uterine neoplasms in contrast to age-
matched sibling control females in none of whom such pathologies
occurred (Table 1). The ovarian cyst phenotype was highly (76%)
penetrant, affecting 16 out of 21 conditional-mutant females. The
cystic ovaries ranged in size from 5–12 mm (Figure 4A) and were
unilateral in 12/16 females and bilateral in 4/16 females. The
affected ovaries contained 1–3 cysts, which is less than the number
present in polycystic ovaries [36]. In addition, Brg1
Wap-Cre mutant
females did not exhibit hirsutism or reduced fertility as young
adults over several litters, which is characteristic of human
polycystic ovarian disease caused by altered hormonal influences
such as hyperandrogenism [37]. We also did not detect a
significant difference in circulating progesterone levels (Figure
S4), which might have provided insight into the polycystic ovaries
or the lack of mammary tumors in Brg1
Wap-Cre mutants.
Histopathological analysis of H&E-stained ovary sections revealed
follicular cysts lined with either spindle cells or columnar cells
characteristic of having apical ciliary structures (Figure 4B). All cysts
contained either serous fluid or varying stages of hemorrhage
Table 2. Phenotype of Brg1
Wap-Cre mutant mice on a Brm-deficient background.
Phenotype
Gender Category Genotype
1 #Litters* Mammary Ovary/Uterus
Female control floxed/floxed, Brm
2/2 3 none none
Female control floxed/floxed, Brm
2/ 3 none none
Female control floxed/floxed, Brm
2/2 3 none none
Female control floxed/floxed, Brm
2/2 2 none none
Female control floxed/floxed, Brm
+/2 2 none none
Female control floxed/floxed, Brm
2/2 3 none none
Female double mutant floxed/floxed, Tg, Brm
2/2 3 none none
Female double mutant floxed/floxed, Tg, Brm
2/2 3 none ovarian cyst
Female double mutant floxed/floxed, Tg, Brm
2/2 2 none ovarian cyst
Female double mutant floxed/floxed, Tg, Brm
2/2 2 none none
Female double mutant floxed/floxed, Tg, Brm
2/2 3 none ovarian cyst
Female double mutant floxed/floxed, Tg, Brm
2/2 2 none ovarian cyst
Female double mutant floxed/floxed, Tg, Brm
2/2 3 none none
Female double mutant floxed/floxed, Tg, Brm
2/2 2 none ovarian cyst
*First pregnancy was at 2–3 months of age, no lactation defects were observed, and all mice were analyzed at 15–19 months of age.
1Tg was hemizygous in each case (Wap-Cre
+/0).
doi:10.1371/journal.pone.0031346.t002
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(Figure 4B, C). Serous cysts were encapsulated by an inner layer of
spindle-shaped cells, a middle layer of granulosa cells, and an outer
layer of spindle cells (Figure 4C). The uterine neoplasm phenotype
was 19% penetrant, occurring in 4 of 21 conditional mutant females
(Table 1). These neoplasms were of 2 histopathologic types: either
histiocytic sarcomas projecting into the uterine lumen (Figure 4D) or
endometrial stromal polyps (Figure 4E, F).
IHC analysis demonstrated that BRG1 is normally expressed in
both the ovary and the uterus. In the ovary, BRG1 protein was
detected in oocytes, granulosa cells, and theca cells within the
follicles (Figure S2B). In the uterus, BRG1 was expressed in a
widespread manner (Figure S2C). In the experiments where we
performed X-Gal staining on R26R:Wap-Cre
+/0 tissues, Cre
activity was detected consistently in the ovary and uterus as well
as in the mammary glands of 10 Wap-Cre transgenic mice but not
in negative controls carrying R26R but lacking the Wap-Cre
transgene. These findings are consistent with endogenous Wap
expression in the ovary and uterus [37]. Ovarian Cre activity was
observed in granuolosa cells within follicles (Figure S5). Similarly,
BRG1 immunostaining was abolished or diminished in these cells
in the Brg1
Wap-Cre mutants (Figure S2D, E). The results presented
above strongly suggest that the generation of the ovarian cysts and
uterine tumors is a cell autonomous process.
Figure 4. Histopathology of ovarian cysts and uterine tumors from Brg1
Wap-Cre mice. A. Control ovary (left) and cystic ovary from a
conditional Brg1
Wap-Cre mutant (right). B. Section of an ovarian cyst stained with H&E at 406magnification. The thin wall of this multilocular structure
is comprised of an inner layer of spindle-shaped cells surrounded by multiple layers of round cells with uniformly sized, round, basophilic nuclei with
scant cytoplasm (arrows). This cyst is filled with a lightly eosinophilic proteinaceous fluid (arrowheads). C. Hemorrhagic ovarian cyst section stained
with H&E at 406magnification. The thin arrow points to a wall of the cyst, and the arrowhead points to a region of hemosiderin-laden macrophages
at the edge of the hemorrhage. D. Histiocytic sarcoma section stained with H&E at 206 magnification. A pleomorphic population of cells with
basophilic round to ovoid nuclei and cytoplasm varying from scant to abundant and foamy are seen infiltrating the myometrium (thin arrows) and
forming a polyp (arrowheads) projecting into the uterine lumen E. Endometrial stromal polyp section stained with H&E at 206magnification. The
polyp (arrows) includes a pedunculated mass (arrowheads) that projects into the uterine lumen. F. Endometrial stromal polyp section stained with
H&E stained at 2006 magnification. The polyp stroma is comprised of spindle cells with variable amounts of cytoplasm and ovoid nuclei; the
structure also includes small blood vessels and small endometrial glands and is covered by a single layered cuboidal to columnar epithelium with
basally located round nuclei.
doi:10.1371/journal.pone.0031346.g004
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We previously demonstrated that Brg1
null/+ mice are susceptible
to mammary tumorigenesis, but the cells of origin were not
identified [16,17]. We now show that this is unlikely to be a
consequence of decreased Brg1 expression in luminal cells as
mammary tumors were never obtained in Brg1
Wap-Cre conditional
mutants in spite of the fact that Brg1 is normally expressed in these
cells and was successfully deleted by forcing the mice to undergo
multiple pregnancies but without any evidence of increased
apoptosis. These findings imply that Brg1 haploisufficiency must
activate an oncogenic process in other cells, either members of the
basal mammary cell compartment and/or stromal cells. Consistent
with this hypothesis is our finding that Brg1 is normally expressed in
thebasalcells ofthemammarygland buttheBrg1 floxed allele could
not be deleted in Brg1
Wap-Cre conditional mutant mice because
expression of Wap and hence Cre is not induced in the basal cells.
Additional support for an important role of Brg1 in mammary stem
cellsis the demonstration ofitsrequirementforembryonicstem (ES)
cell self-renewal and pluripotency [38,39], as well as other, more
restricted, types of stem cells [40,41]. A Brg1 stem/progenitor cell-
restricted function in the mammary gland is also consistent with the
diverse histopathological characteristics and transcriptome profiles
ofBrg1
null/+ tumors[17].ItmayalsoexplainwhydepletionofBRG1
from MCF-10A mammary cells, which have characteristics of non-
malignant luminal cells, did not increase their proliferative activity
nor confer a tumor-like phenotype [42].
The restricted expression of Wap-Cre to the luminal cells in the
mammary gland may explain why only certain Wap-Cre
conditional mutants develop highly penetrant tumor phenotypes.
For example, Wap-Cre driven mutation of Smad4 and Brca2 causes
a very high frequency of affected mice to develop mammary
tumors (100% and 77%, respectively), whereas only 15% of mice
with Wap-Cre driven mutation of Brca1 develop mammary tumors
and no tumors are obtained following Wap-Cre driven mutation of
Pparc or Stat3 [43–47]. Failure of tumorigenesis would be expected
if the gene being targeted for deletion was not expressed in a
luminal cell, or not required, or involved in a pathway whose
perturbation would lead to deregulated growth of a luminal cell. In
addition, Wap-Cre driven mutations that require other genetic or
epigenetic changes to be accumulated might not lead to tumors
because of the transient lifespan of the luminal compartment.
SWI/SNF-related complexes are essential for the development
of many cell lineages [48], which suggests that they might be
required for the viability of most or all primary cell types. In fact,
the only cells previously known to deficient for both BRG1 and
BRM are certain tumor-derived cell lines [2,5], and these tumor
cells may have subverted the normal requirement for at least one
catalytic subunit via inhibition of apoptosis. However, our present
findings now offer a potential alternative explanation; i.e., that
SWI/SNF-related complexes may be dispensable in mammary
luminal cells. Here we show that neither Brg1 nor Brm are required
for a morphologically- and functionally-normal mammary gland
and their absence did not affect the ability of the gland to support
the repeated production of litters of normal-sized pups. Thus,
SWI/SNF-related complexes catalyzed by either BRG1 or BRM
must be dispensable for the viability and normal functionality of
mammary luminal cells, in spite of previous experiments with
EpH4 cells expressing a dominant-negative BRG1 suggesting that
casein expression is dependent on SWI/SNF catalytic activity
[49]. It is likely that other primary cell types can also survive in the
absence of BRG1/BRM-catalyzed SWI/SNF complexes, and we
have evidence from Villin-Cre experiments that this is the case for
intestinal epithelial cells (data not shown).
Although Brg1
Wap-Cre mice did not develop mammary tumors,
they did become susceptible to the formation of ovarian cysts and
uterine tumors. The ovarian cysts were associated with a loss of
BRG1 in granulosa cells (Figure S5), whereas our previous analysis
of Brg1
Zp3-Cre conditional mutants indicated that ovarian cysts did
not develop when Brg1 was deleted in developing oocytes [50].
These results are compatible with ovarian cysts arising from
functional defects in somatic support cells rather than germ cells.
BRG1 could prevent cyst formation in wild-type cells through its
well-known role in development and differentiation [2,48].
Alternatively, it could be promoting apoptosis to promote the
death of immature ovarian follicles (i.e., artesia) [36]. The uterine
neoplasms are also noteworthy because few genetically engineered
mouse models of uterine cancer other than Pten have been
described [51–53]. The Brg1
Wap-Cre ovarian cyst and uterine tumor
phenotype is also reminiscent of recent deep-sequencing efforts
demonstrating consistent mutations of another SWI/SNF subunit,
ARID1A/BAF250a,i n,30% and ,50% of human ovarian clear
cell carcinomas and endometrial carcinomas, respectively [54,55].
Our data also support the observation that BRG1 is downregu-
lated in human cervical carcinomas [56]. In summary, our results
add weight to the idea that SWI/SNF-related complexes have an
important function in preventing the development of cancers,
particularly within the stem/progenitor compartments of cells in
certain tissues.
Materials and Methods
Ethics statement, mice, and genotyping
All mouse experiments were approved by the Institutional
Animal Care and Use Committees (IACUC) review board at the
University of North Carolina as approved protocol ID #10-026
and were performed in accordance with federal guidelines. Wap-
Cre transgenic mice were obtained from the Jackson Laboratory
(Bar Harbor, ME, USA). The Brg1 floxed and Dfloxed alleles were
genotyped by PCR as previously described [21]. Quantification of
the relative abundance of the Brg1 Dfloxed allele was performed by
qPCR and normalized to Gapdh as previously described [26].
Histology
Normal tissues and cystic or tumor tissues were fixed in 4%
paraformaldehyde, embedded in paraffin, and 5 mm sections were
cut according to standard procedures. Sections were either stained
with H&E or processed for IHC using a BRG1 rabbit polyclonal
antibody (Upstate/Millipore #07-478, Temecula, CA, USA) or
for TUNEL assays (Chemicon/Millipore, Temecula, CA, USA)
according to the manufacturer’s recommendations. The TUNEL
positive control was provided by the manufacture and consisted of
human promyelocytic leukemia treated with actinomycin D.
Whole mount preparations of mammary glands and X-Gal
staining of R26R (Rosa-lox-stop-lox-LacZ) tissues were performed
following standard procedures. Serum progesterone levels were
determined by ELISA.
Isolation of mammary cell populations
Mammary glands were dissected from 8–12 week old, female
C57BL/6J mice before or after induction of pregnancy (E13.5 or
E17.5) as indicated. Single-cell suspensions were generated and
analyzed by flow cytometry as previously described with minor
modifications [18]. Briefly, mammary glands were digested
overnight at 37uC in DMEM/F12 medium containing 1 mg/
mL collagenase A (Roche) and 100 U/mL hyaluronidase (Sigma).
After vortexing and lysis of red blood cells in NH4Cl, the nucleated
cells were further dissociated in 0.25% trypsin, 5 mg/mL dispase
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mesh to remove cell clumps and aggregates. Cells were then
treated with anti-CD16/CD32 Fcc III/II receptor antibody (BD
Pharmingen) and subsequently with anti-CD45 (Biolegend),
Ter119 (Biolegend), CD31(BD Pharmingen)-biotinylated antibod-
ies followed by streptavidin-phycoerythrin (SA-PE, BD Pharmin-
gen) and with fluorescein isothiocyanate (FITC)-conjugated anti-
CD49f (clone GoH3, BD Pharmingen) and allophycoerythrin
(APC)-conjugated anti-CD24 (clone M1/69, Biolegend) to isolate
the fractions indicated on a FACSDiva or Influx (BD) fluores-
cence-activated cell sorter (FACS).
RT-qPCR
RNA from mammary cell fractions was isolated using
Absolutely RNA nano and microprep kits (Stratagene, La Jolla,
CA, USA) and reverse transcribed using SuperScript III RT
(Invitrogen) according to the manufacturer’s protocol. Validated
TaqMan assays (Applied Biosystems, Foster City, CA, USA) were
used with TaqMan gene expression master mix (Applied
Biosystems) on an ABI 7300 instrument under default cycling
conditions (95uC 15 s followed by 60uC 1 min for 45 cycles). Gapdh
was used as a normalization control. Relative expression levels
were determined using DDCt method. Control reactions lacking
RT yielded little or no signal.
Supporting Information
Figure S1 Representative FACS plots showing the
expression of CD24 and CD49f at various developmental
stages after the depletion of hematopoietic and endo-
thelial cells (CD45
+CD31
+Ter119
+). Mammary cells were
isolated from adult virgin (left) and pregnant mice at E13.5
(middle), and E17.5 (right). CD24
+CD49f
low/2, CD24
+CD49f
+,
and CD24
+CD49f
high populations were isolated as shown above.
(TIF)
Figure S2 BRG1 IHC of mouse tissues. (A) Wild-type
mammary gland section at 10006 magnification showing strong
nuclear expression in mammary epithelial cells (luminal cells in
particular) and stromal cells. (B) Wild-type ovarian section at 4006
magnification showing strong staining throughout follicle includ-
ing oocyte, granulosa and theca cells. (C) Wild-type uterine section
at 10006 magnification showing widespread expression. (D, E)
Expression in granulosa cells within ovarian follicle is high in wild-
type mice (D) and markedly diminished in conditional mutant
mice (E).
(TIF)
Figure S3 Wap-Cre-mediated deletion of Brg1 does not
exacerbate the Wap-T121 phenotype. Kaplan-Meier survival
curve showing the fraction of palpable mammary tumor free mice.
(TIF)
Figure S4 Serum progesterone levels from controls
(Brg1
fl/fl) and mutants (Brg1
fl/fl:Wap-Cre
+/0) mice while
non-pregnant and pregnant (at E17.5). Histograms repre-
sent mean 6 SE for 3 independent experiments.
(TIF)
Figure S5 Ovary section from mouse carrying Wap-Cre
transgene and R26R reporter following X-Gal staining.
Blue Cre-positive cells are present in granulosa cells within the
follicle.
(TIF)
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